Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) are being increasingly used after primary treatment of early-stage tumors to treat any residual disease and prevent recurrence. Herein, we provide a comprehensive review of pivotal clinical studies demonstrating efficacy and safety outcomes when IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Abboud, Karen, Umoru, Godsfavour, Esmail, Abdullah, Abudayyeh, Ala, Murakami, Naoka, Al-Shamsi, Humaid O., Javle, Milind, Saharia, Ashish, Connor, Ashton A., Kodali, Sudha, Ghobrial, Rafik M., Abdelrahim, Maen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000896/
https://www.ncbi.nlm.nih.gov/pubmed/36900226
http://dx.doi.org/10.3390/cancers15051433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000896/
https://www.ncbi.nlm.nih.gov/pubmed/36900226
http://dx.doi.org/10.3390/cancers15051433

Ejemplares similares